Document is current

Article History

Received: 26 April 2023

Accepted: 23 May 2024

First Online: 2 August 2024

Declarations

:

: This analysis of the Clinformatics® database was a secondary data analysis based on patient healthcare information from a deidentified database, from which patients could not be deanonymized. As dictated by Title 45 Code of Federal Regulations 2011 (Title 45, Part 46, Subpart A, Sect. 46.101(b)(4); Page 129–130) (available at . Accessed April 22, 2024), this analysis was conducted under an exemption from Institutional Review Board oversight for US-based studies using de-identified healthcare records, and for which informed consent was not applicable. The research reported in this paper adhered to guidelines set forth by the Helsinki Declaration as revised in 2013.

: Not applicable.

: Nasreen Khan, Helene Ostojic, XiaoLong Jiao, Guifang Chen, Wenlong Lin, and Amanda Bruno are employees of Bayer. Tanios Bekaii-Saab has consulting or advisory roles with AbbVie, Amgen (Inst), Arcus Biosciences (Inst), AstraZeneca, Bayer (Inst), BeiGene, Boehringer Ingelheim, Celularity, Daiichi Sankyo/UCB Japan, Deciphera, Eisai, Exact Sciences, Foundation Medicine, Illumina, Immuneering, Incyte (Inst), Ipsen (Inst), Janssen, Kanaph Therapeutics, Lilly (Inst), Natera, Pfizer (Inst), Roche/Genentech (Inst), Seagen (Inst), SOBI, Stemline Therapeutics, Treos Bio, and other relationships with 1Globe Health Institute, AstraZeneca, Exelixis, FibroGen, Imugene, Lilly, Merck (Inst), Pancreatic Cancer Action Network, Replimune, Sun Biopharma, Suzhou Kintor Pharmaceuticals, UpToDate, and Xilis.